The IDH1 mutant AML cells carrying IDH1R132H, IDH1R132C, IDH1R132G, IDH1R132L and IDH1R132S mutations undergo myeloid differentiation when treated with BAY1436032, a novel pan mutant IDH1 inhibitor which specifically inhibits R-2HG production and colony growth in these cells. Here, IDH1 is linked to acute myeloid leukemia.